Abstract
Transfusion-related acute lung injury (TRALI) is a subcategory of acute lung injury (ALI). As such, there are many similarities between the syndromes, both clinically and pathophysiologically. Pulmonary changes in fibrin turnover have emerged as a hallmark of ALI, thereby initiating studies investigating the potential of therapeutic interventions aimed at ameliorating this so-called pulmonary coagulopathy. Enhanced coagulation and impaired fibrinolysis are probably also important features of TRALI. In particular, platelets play an important role in mediating injury during a TRALI reaction. In this narrative review, the evidence of the role of coagulopathy and platelet activation in TRALI is discussed. Given that host risk factors for acquiring TRALI have been identified and that there is a time frame in which a preventive strategy in patients at risk for TRALI can be executed, preventive strategies are suggested. In this review, we discuss potential preventive anticoagulant interventions.
Keywords: TRALI, platelets, acetylsalicylic acid, coagulation, fibrinolysis, ALI, therapy, fibrin turnover, pulmonary coagulopathy, anticoagulant interventions
Current Pharmaceutical Design
Title:Coagulopathy as a Therapeutic Target for TRALI: Rationale and Possible Sites of Action
Volume: 18 Issue: 22
Author(s): Pieter R. Tuinman, Marcus J. Schultz and Nicole P. Juffermans
Affiliation:
Keywords: TRALI, platelets, acetylsalicylic acid, coagulation, fibrinolysis, ALI, therapy, fibrin turnover, pulmonary coagulopathy, anticoagulant interventions
Abstract: Transfusion-related acute lung injury (TRALI) is a subcategory of acute lung injury (ALI). As such, there are many similarities between the syndromes, both clinically and pathophysiologically. Pulmonary changes in fibrin turnover have emerged as a hallmark of ALI, thereby initiating studies investigating the potential of therapeutic interventions aimed at ameliorating this so-called pulmonary coagulopathy. Enhanced coagulation and impaired fibrinolysis are probably also important features of TRALI. In particular, platelets play an important role in mediating injury during a TRALI reaction. In this narrative review, the evidence of the role of coagulopathy and platelet activation in TRALI is discussed. Given that host risk factors for acquiring TRALI have been identified and that there is a time frame in which a preventive strategy in patients at risk for TRALI can be executed, preventive strategies are suggested. In this review, we discuss potential preventive anticoagulant interventions.
Export Options
About this article
Cite this article as:
R. Tuinman Pieter, J. Schultz Marcus and P. Juffermans Nicole, Coagulopathy as a Therapeutic Target for TRALI: Rationale and Possible Sites of Action, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023267
DOI https://dx.doi.org/10.2174/1381612811209023267 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment of Choroidal Neovascularization in High Myopia
Current Drug Targets Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials
Current Drug Targets The Blood-Brain Barrier as a Cause of Obesity
Current Pharmaceutical Design Nanomedical Strategies for Targeting Skin Microbiomes
Current Drug Metabolism Recent Advances in Polymer-based Wound Dressings for the Treatment of Diabetic Foot Ulcer: An Overview of State-of-the-art
Current Drug Targets Severe OSA Leading to Long Pauses in 24-h Holter ECG Reversed with CPAP
Current Cardiology Reviews Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis
Infectious Disorders - Drug Targets Dopamine Administration in Very Low Birth Weight Preterm Infants:Emerging Issues on Endocrine Effects
Current Pediatric Reviews Periodontal Disease and Periodontal Tissue Regeneration
Current Stem Cell Research & Therapy Chronic Hypoxia Potentiates Age-Related Oxidative Imbalance in Brain Vessels and Synaptosomes
Current Neurovascular Research Measurement of Extravascular Lung Water in Critically Ill Patients
Current Respiratory Medicine Reviews Transmission, Prevention and Therapeutic Strategies for COVID-19: Updates and Challenges
Coronaviruses Biochemical Screening for in utero Drug Exposure
Drug Metabolism Letters Pharmacokinetic Interaction Between Verapamil and Methylxanthine Derivatives in Mice
Drug Metabolism Letters Sol-gel Encapsulation of Biomolecules and Cells for Medicinal Applications
Current Topics in Medicinal Chemistry Dengue Fever: Theories of Immunopathogenesis and Challenges for Vaccination
Inflammation & Allergy - Drug Targets (Discontinued) Perspective of Molecular Hydrogen in the Treatment of Sepsis
Current Pharmaceutical Design The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology